TIDMFUM
RNS Number : 5872K
Futura Medical PLC
17 December 2018
Futura Medical to Host R&D Day in February 2019
17 December 2018
Futura Medical plc (AIM: FUM) (the "Company"), a pharmaceutical
company developing a portfolio of innovative products for sexual
health and pain relief, today announces plans to host an R&D
Day in London for analysts and institutional investors on Monday 11
February 2019.
The event will feature a presentation from a Key Opinion Leader
in erectile dysfunction ("ED") and will provide an opportunity to
hear about the Company, its R&D strategy with a focus on its
DermaSys(R) drug delivery technology and lead product MED2005, a
topical glyceryl trinitrate ("GTN") gel for the treatment of
ED.
James Barder, Chief Executive Officer of Futura Medical, said:
"We are looking forward to hosting the event which will build on
our initial Advisory Panel meeting hosted by Futura at the 19th
Annual Fall Scientific Meeting of Sexual Medicines Society of North
America in November 2018, and was extremely well received and
productive. The Advisory Panel were unanimous in their view that
there has been little recent credible innovation in the treatment
of ED. They were therefore excited by the meaningful PK and Phase 2
findings presented on our lead programme MED2005, demonstrating the
potential of MED2005 as both a topical and fast-acting erectile
dysfunction treatment, key differentiators to other ED products on
the market. There was also a unanimous desire by the panel to
remain involved with the development programme for MED2005 and the
panel look forward to reviewing the results from our ongoing Phase
3 trial when published in Q4 2019."
Dr. Wayne J.G. Hellstrom is Professor of Urology and Chief of
Andrology at Tulane University School of Medicine in New Orleans
and member of the Futura Medical Advisory Panel, said: "The
treatment of ED has not seen any new clinical products for nearly
two decades. MED2005 is a novel glyceryl trinitrate (GTN) topical
gel with an enhanced absorption delivery system. After application
to the glans penis, there is a rapid onset of action (5-10 mins in
70% of spontaneous attempts at intercourse) in contrast to current
oral PDE5i's, which can take 30-90 mins to act. This novel topical
therapy is easy to use, does not have any food or alcohol
interactions, and has excellent tolerability for both patient and
partner.
"I am excited to be part of an advisory panel helping to shape
the future programme for MED2005 as it enters Phase 3 studies, and
I look forward to ultimate approval by the FDA and regulators
around the world. It offers new hope to patients who, for whatever
reason, are dissatisfied with current therapies or are precluded
from their use."
In October 2018, Futura announced that the first patient had
been enrolled in the first Phase 3 study, ("FM57") of MED2005 that
will recruit approximately 1,000 patients with mild, moderate or
severe ED across nine countries in Central and Eastern Europe. The
Phase 3 study remains on track, with headline data expected by the
end of 2019.
For further information on the R&D day, or to register your
interest, please contact Optimum Strategic Communications at
futuramedical@optimumcomms.com. Further information will be made
available in January 2019.
The event will be webcast and will be made available on the
investor section of website shortly after the event.
ENDS
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Broker:
N+1 Singer
Aubrey Powell/ Ben Farrow (Corporate Finance)
Mia Gardner / Tom Salvesen (Corporate Broking)
Tel: +44 (0) 20 7496 3000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Ellie Blackwell
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) drug delivery technology.
These products are optimised for clinical efficacy, safety,
administration and patient convenience and are developed for the
prescription and consumer healthcare markets as appropriate.
Current therapeutic areas are sexual health, including erectile
dysfunction, and pain relief. Development and commercialisation
strategies are designed to maximise product differentiation and
value creation whilst minimising risk.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
Dr. Wayne J.G. Hellstrom
Dr. Wayne J.G. Hellstrom is Professor of Urology and Chief of
Andrology (male infertility and sexual dysfunction) at Tulane
University School of Medicine in New Orleans, where he has been
since 1988. His practice is specialized in the diagnosis and
treatment of sexual dysfunction including Peyronie's disease,
surgical and vascular reconstruction, prosthetic surgery, male
infertility (both surgical and medical therapies), BPH, and
urethral stricture disease.
A clinician, author, and lecturer, Hellstrom has published
numerous peer-reviewed articles in professional publications and
has contributed numerous chapters in textbooks. He also is the
editor of "Male Infertility and Sexual Dysfunction" and "The
Handbook of Sexual Dysfunction."
Dr. Hellstrom earned his undergraduate and medical degrees at
McGill University in Montreal, completed his urology residency at
the University of California at San Francisco, and his fellowship
at the University of California at Davis. He has been awarded many
honours in the field of urology, male infertility, and erectile
dysfunction.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCQZLFFVLFXFBL
(END) Dow Jones Newswires
December 17, 2018 02:00 ET (07:00 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2024 to May 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From May 2023 to May 2024